Better Therapeutics, Inc. (BTTX): Price and Financial Metrics


Better Therapeutics, Inc. (BTTX): $2.03

-0.24 (-10.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BTTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

BTTX Stock Price Chart Interactive Chart >

Price chart for BTTX

BTTX Price/Volume Stats

Current price $2.03 52-week high $29.40
Prev. close $2.27 52-week low $0.91
Day low $1.94 Volume 4,820,200
Day high $2.48 Avg. volume 4,092,596
50-day MA $1.80 Dividend yield N/A
200-day MA $5.73 Market Cap 47.92M

Better Therapeutics, Inc. (BTTX) Company Bio


As of October 29, 2021, Mountain Crest Acquisition Corp. II was acquired by Better Therapeutics, Inc., in a reverse merger transaction. Mountain Crest Acquisition Corp. II. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.


BTTX Latest News Stream


Event/Time News Detail
Loading, please wait...

BTTX Latest Social Stream


Loading social stream, please wait...

View Full BTTX Social Stream

Latest BTTX News From Around the Web

Below are the latest news stories about Better Therapeutics Inc that investors may wish to consider to help them evaluate BTTX as an investment opportunity.

Better Therapeutics to Participate in Two Upcoming Investor Events

SAN FRANCISCO, January 20, 2022--Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Chief Executive Officer, is scheduled to participate in two upcoming investor events as follows:

Yahoo | January 20, 2022

Use this app and call me in the morning: The promise of prescription digital therapeutics

When it comes to treating diseases, some doctors are looking beyond traditional medicines as therapies. A growing number of health care professionals are recognizing the value of prescription digital therapeutics (PDTs), a type of evidence-based software program that provides behavioral therapy or other type of therapeutic intervention. Digital therapeutics can...

Seeking Alpha | January 8, 2022

Better Therapeutics Highlights Recent Progress and Updates Outlook Through Q1 2022

SAN FRANCISCO, January 06, 2022--Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today provided an update on recent progress.

Yahoo | January 6, 2022

Better Therapeutics Appoints Deepti Sodhi Jaggi, PharmD, as Chief Strategy Officer

SAN FRANCISCO, November 30, 2021--Better Therapeutics, Inc. ("Better Therapeutics"; NASDAQ: BTTX), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the appointment of Deepti Sodhi Jaggi, PharmD, as its Chief Strategy Officer.

Yahoo | November 30, 2021

Chardan Capital Thinks Mountain Crest Acquisition II’s Stock is Going to Recover

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Mountain Crest Acquisition II (BTTX – Research Report) today and set a price target of $17.00. The company's shares closed last Tuesday at $6.41, close to its 52-week low of $6.36. According to TipRanks.com, Nakae is a 5-star analyst with an average return of 18.8% and a 47.5% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Emergent Biosolutions, and Kaleido Biosciences. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mountain Crest Acquisition II with a $17.00 average price target, representing a 145.7% upside.

Christine Brown on TipRanks | November 24, 2021

Read More 'BTTX' Stories Here

BTTX Price Returns

1-mo 111.57%
3-mo -30.72%
6-mo -71.25%
1-year -79.66%
3-year N/A
5-year N/A
YTD -56.34%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6071 seconds.